Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile

详细信息    查看全文

• 作者：Francesca R. Mauro ; Stefano Molica ; Luca Laurenti ; Agostino Cortelezzi ; Angelo M. Carella ; Francesco Zaja ; Annalisa Chiarenza ; Francesco Angrilli ; Francesco Nobile ; Roberto Marasca ; Caterina Musolino ; Maura Brugiatelli ; Alfonso Piciocchi ; Marco Vignetti ; Paola Fazi ; Giuseppe Gentile ; Maria S. De Propris ; Irene Della Starza ; Marilisa Marinelli ; Sabina Chiaretti ; Ilaria Del Giudice ; et al.
• 关键词：Chronic lymphocytic leukemia ; CLL ; Young ; Biology ; Fludarabine ; Alemtuzumab
• 刊名：Leukemia Research
• 出版年：February, 2014
• 年：2014
• 卷：38
• 期：2
• 页码：198-203
• 全文大小：1185 K

文摘

In 45, 鈮?0 years old patients with CLL and an adverse biologic profile, a front-line treatment with Fludarabine and Campath (Alemtuzumab^庐) was given. The overall response rate was 75.5%, the complete response rate (CR) 24.4% with the lowest CR rates, 16.7% and 8.3%, in 11q and 17p deleted cases. The 3-year progression-free survival (PFS) and overall survival were 42.5% and 79.9%, respectively. PFS was significantly influenced by CLL duration, beta2-microglobulin, and improved by post-remissional stem cell transplantation. Front-line fludarabine and alemtuzumab showed a manageable safety profile and evidence of a benefit in a small series of CLL patients with adverse biologic features.